Immix Biopharma
direct path to line therapy in clinical trial plan nee ara | Immix Biopharma
Company
Deck Type
Sector
Industry
Deck date
January 2024
Slide
55 of 64
Similar slides by Immix Biopharma
See diffirences between slides (animation)
Investor Presentation
December 2023
direct path to line therapy in clinical trial plan cold | Immix Biopharma
Investor Presentation
November 2023
direct path to line therapy in clinical trial plan cold | Immix Biopharma
Investor Presentation
November 2023
direct path to line therapy in clinical trial plan cold | Immix Biopharma
Investor Presentation
November 2023
direct path to line therapy in clinical trial plan cold | Immix Biopharma
Related slides by other companies
RayzeBio
IPO
September 2023
phase trial in first line combination treatment of | RayzeBio
AstraZeneca
Results
November 2024
| AstraZeneca
AstraZeneca
Results
November 2024
solid | AstraZeneca
MAIA Biotechnology
Investor Presentation
January 2024
thio trial planned | MAIA Biotechnology
Other recent decks by Immix Biopharma
See all presentations (11 decks)
Investor Presentation
March 2024
Investor Presentation
December 2023
Investor Presentation
November 2023
Investor Presentation
November 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights